



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2304807 C 2002/05/28

(11)(21) **2 304 807**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 1998/09/18
(87) Date publication PCT/PCT Publication Date: 1999/04/01
(45) Date de délivrance/Issue Date: 2002/05/28
(85) Entrée phase nationale/National Entry: 2000/03/22
(86) N° demande PCT/PCT Application No.: US 1998/019521
(87) N° publication PCT/PCT Publication No.: 1999/015136
(30) Priorité/Priority: 1997/09/22 (08/935,181) US

(51) Cl.Int.⁶/Int.Cl.⁶ A61K 7/06
(72) Inventeurs/Inventors:
HENRY, JAMES P., US;
AHLUWALIA, GURPREET S., US
(73) Propriétaire/Owner:
THE GILLETTE COMPANY, US
(74) Agent: MACRAE & CO.

(54) Titre : REDUCTION DE LA CROISSANCE DE LA PILOSITE
(54) Title: REDUCTION OF HAIR GROWTH

(57) Abrégé/Abstract:

Mammalian hair growth is reduced by applying an inhibitor of aminoacyl-tRNA synthetase to the skin.



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 7/06	A1	(11) International Publication Number: WO 99/15136 (43) International Publication Date: 1 April 1999 (01.04.99)
(21) International Application Number: PCT/US98/19521 (22) International Filing Date: 18 September 1998 (18.09.98) (30) Priority Data: 08/935,181 22 September 1997 (22.09.97) US (71)(72) Applicant and Inventor: HANDELMAN, Joseph, H. [US/US]; 26 West 61st Street, New York, NY 10023 (US). (72) Inventors: HENRY, James, P.; 10257 Meadow Fence Court, Myersville, MD 21773 (US). AHLUWALIA, Gurpreet, S.; 8632 Stableview Court, Gaithersburg, MD 20882 (US). (74) Agents: HANDELMAN, Joseph, H.; Ladas & Parry, 26 West 61st Street, New York, NY 10023 (US) et al.		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: REDUCTION OF HAIR GROWTH (57) Abstract Mammalian hair growth is reduced by applying an inhibitor of aminoacyl-tRNA synthetase to the skin.		

- 1 -

REDUCTION OF HAIR GROWTH

The invention relates to reducing hair growth in mammals.

A main function of mammalian hair is to provide environmental protection. However, that function has largely been lost in humans, in whom hair is kept or removed from various parts of the body essentially for cosmetic reasons. For example, it is generally preferred to have hair on the scalp but not on the face.

Various procedures have been employed to remove unwanted hair, including shaving, electrolysis, depilatory creams or lotions, waxing, plucking, and therapeutic antiandrogens. These conventional procedures generally have drawbacks associated with them. Shaving, for instance, can cause nicks and cuts, and can leave a perception of an increase in the rate of hair regrowth. Shaving also can leave an undesirable stubble. Electrolysis, on the other hand, can keep a treated area free of hair for prolonged periods of time, but can be expensive, painful, and sometimes leaves scarring. Depilatory creams, though very effective, typically are not recommended for frequent use due to their high irritancy potential. Waxing and plucking can cause pain, discomfort, and poor removal of short hair. Finally, antiandrogens -- which have been used to treat female hirsutism -- can have unwanted side effects.

It has previously been disclosed that the rate and character of hair growth can be altered by applying to the skin inhibitors of certain enzymes. These inhibitors include inhibitors of 5-alpha reductase, ornithine decarboxylase, S-adenosylmethionine decarboxylase, gammaglutamyl transpeptidase, and transglutaminase. See, for example, Breuer et al., U.S. Pat. No. 4,885,289; Shander, U.S. Pat. No. 4,720,489; Ahluwalia, U.S. Pat. No. 5,095,007; Ahluwalia et al., U.S. Pat. No. 5,096,911; Shander et al., U.S. Pat. No. 5,132,293; and Shander et al, U.S. Pat. No. 5,143,925.

Aminoacyl-tRNA synthetases are a family of enzymes that are involved in cellular protein synthesis. In particular, the enzymes participate in the activation of amino acids and the subsequent linkage of the amino acids to corresponding tRNAs. There is at least one specific aminoacyl-tRNA synthetase and tRNA for each of the twenty natural amino acids that make up protein molecules. Aminoacyl-tRNA synthetases are discussed, for example, in P. Schimmel (1987) Ann. Rev.

- 2 -

Biochem. 56:125-158.

It has now been found that unwanted mammalian (including human) hair growth -- particularly androgen-stimulated hair growth -- can be reduced by applying to the skin a dermatologically acceptable composition including an inhibitor of an aminoacyl-tRNA synthetase in an amount effective to reduce hair growth. The unwanted hair growth which is reduced may be normal hair growth, or hair growth that results from an abnormal or diseased condition.

Examples of aminoacyl-tRNA inhibitors include S-trityl-L-cysteine; L-asparaginamide; 4-aza-DL-leucine; DL-serine hydroxamate; proflavine (hemisulfate salt); L-isoleucinol; N-phenylglycine; L-leucinol; L-methioninol; phe-leu-amide; tyramine; L-isoleucinol; 3,4-dehydro-DL-proline; S-carbamyl-L-cysteine; α -methyl-DL-methionine; chloro-L-alanine; cis-hydroxy proline; L-prolinol; L-histidonol; L-tyrprophan hydroxamate; DL-4-thiaisleucine; DL-amino- ϵ -caprolactam; L-aspartic acid amide; DL- β -hydroxynorvaline; cis-4-fluoro-L-proline; trans-4-fluoro-L-carboxylic acid; α -methyl-DL-histidine; N-formyl-L-histidine; L-2-amino-3-sulfamoylpropionic acid; L-aspartic acid- β -hydroxamate; β -cyano-L-alanine; selenocystamine; 4-amino-n-butyric acid amide; DL-5-hydroxylysine; L-lysinhydroxamate; 3-(N-phenylacetyl)amino-2,6-piperidinedione (antineoplaston A10); 4-amino-4 phosphonobutyric acid; ethionamide; 1,2-diamino-3-(4-imidazolyl)propane (histidinamine); α -methylhistidine; (S)-2-methylbutylamine; L-O-methylthreonine; DL-armentomycin (2-amino-4,4-dichlorobutyric acid); DL-3-dehydroarmentomycin; DL-3-hydroxyleucine; 5,5,5-trifluoro-DL-leucine; β -(3-aminocyclohexyl)-DL-alanine; DL-p-chloroamphetamine; trans-2,6-diaminohex-4-enoic acid; DL-2,6-dipthalimidocaproic acid methyl ester; DL-5-hydroxylysine; L-lysinhydroxamate; DL-4-oxalysine; DL-4-selenalysine; L-methioninamide; 2-amino-4-methylhex-4-enoic acid; (1S,2S)-2-amino-1-phenyl-1,3-propanediol; N-benzyl-D-amphetamine; N-benzyl-L-phenylalanine; N-benzyl-D-phenylethylamine; 1,3-bis(acetoxy)-2-nitro-1-phenylpropane (fenitropan); 1,2-diamino-3-(2,6-dichlorophenyl)propane; 1,2-diamino-3-hydroxy-5-phenylpentane; 1,2-diamino-3-phenylpropane; N-(2,6-dichlorobenzylidene)-2-phenylethylamine; N-(2,6-dichlorobenzyl)-2-phenylethylamine; N-(4-fluorobenzyl)-L-phenylalanine; DL-2-fluorophenylalanine; 2-hydroxyethyl-2-phenylammonium sulfate; α - and β -methyl-DL-phenylalanine; L-

- 3 -

phenylalaninol; L- α -phenylglycine; DL-threo- β -phenylserine; β -2-thienyl-DL-alanine; N-trifluoroacetyl-L-phenylalanine cyclohexyl ester; 2-aminomethyl-4-isopropoxy-pyrrolidine oxalate; 2-amino-methylpyrrolidine; L-4-thiaproline; N-benzylethanolamine; N-(2,6-dichlorobenzyl)ethanolamine; N-(2,6-dichloro-
 5 benzylidene)ethanolamine; DL- β P-hydroxyleucine; 1,2-diamino-5-phenyl-3-pentanol; DL-7-azatryptophan, DL-4- and DL-6-fluorotryptophan; 5-hydroxy-tryptamine; L-5-hydroxytryptophan; DL- α -methyltryptamine; α - and β -methyl-DL-tryptophan, tryptamine; DL-2-amino-1-(4-hydroxyphenyl)-1-propanol; DL-3-fluoro-tyrosine; 3-iodo-L-tyrosine; 3-nitro-L-tyrosine; L-tyrosinol $\cdot$ HCl; L-threo-2-amino-3-
 10 chlorobutyric acid; hexafluoro-DL-valine; DL-norvaline; L-4-thialysine; DL-ethionine; N,N'-di-CBZ-L-lysin; DL-3-fluorophenylalanine; DL-4-fluorophenylalanine; and DL-3,4-dihydroxyphenylalanine. These compounds are known.

Many of the examples of aminoacyl-tRNA inhibitors are amino acid analogous and inhibit the specific aminoacyl-tRNA synthetase associated with the
 15 analogous amino acid, although a particular inhibitor may sometimes inhibit aminoacyl-tRNA synthetase associated with more than one amino acid. As used herein, "inhibitor of [name of amino acid] aminoacyl-tRNA synthetase" means a compound that inhibits at least the aminoacyl-tRNA associated with the amino acid. The amino acid may be one of the 20 naturally occurring amino acids (e.g., leucine,
 20 serine, etc.), or some other amino acid. As used herein, "aminoacyl-tRNA synthetase inhibitors" and a "inhibitor of aminoacyl-tRNA synthetase" means a compound that inhibits one or more aminoacyl-tRNA synthetase.

The aminoacyl-tRNA synthetase inhibitor preferably is incorporated in a topical composition that includes a non-toxic dermatologically acceptable
 25 vehicle or carrier which is adapted to be spread upon the skin. Examples of suitable vehicles are acetone, alcohols, or a cream, lotion, or gel which can effectively deliver the active compound. A vehicle is disclosed in U.S. Pat. No. 5,648,394. In addition, a penetration enhancer may be added to the vehicle to further enhance the effectiveness of the formulation.

30 The concentration of the inhibitor in the composition may be varied over a wide range up to a saturated solution, preferably from 0.1% to 30% by weight or even more; the reduction of hair growth increases as the amount of

- 4 -

inhibitor applied increases per unit area of skin. The maximum amount effectively applied is limited only by the rate at which the inhibitor penetrates the skin. The effective amounts may range, for example, from 10 to 3000 micrograms or more per square centimeter of skin.

- 5 A composition may include more than one aminoacyl-tRNA synthetase inhibitor. For example, the composition may include two inhibitors of an aminoacyl-tRNA synthetase associated with a particular amino acid, or may include an inhibitor of an aminoacyl-tRNA synthetase associated with a first amino acid and an inhibitor of an aminoacyl-tRNA synthetase associated with a second amino acid.
- 10 The composition optionally may also include other compounds that are known to reduce hair growth when applied topically.

- The composition should be topically applied to a selected area of the body from which it is desired to reduce hair growth. For example, the composition can be applied to the face, particularly to the beard area of the face, i.e., the cheek,
- 15 neck, upper lip, and chin. The composition can also be applied to the legs, arms, torso or armpits. The composition is particularly suitable for reducing the growth of unwanted hair in women suffering from hirsutism or other conditions. The duration of treatment to achieve a perceived reduction in hair growth may vary depending upon, for example, the severity and location of the unwanted hair growth.
- 20 In humans, the composition, for example, may be applied once or twice a day, or even more frequently, for two weeks to six months (e.g., three months) to achieve a perceived reduction in hair growth. Reduction in hair growth is demonstrated when the frequency or hair removal is reduced, or the subject perceives less hair on the treated site, or quantitatively, when the weight of hair removed by shaving (i.e., hair
- 25 mass) is reduced.

- Male intact Golden Syrian hamsters are considered acceptable models for human beard hair growth in that they display oval shaped flank organs, one on each side, each about 8 mm. in major diameter, which grow thick black and coarse hair similar to human beard hair. These organs produce hair in response to
- 30 androgens in the hamster. To evaluate the effectiveness of a composition including an aminoacyl-tRNA synthetase inhibitor, the flank organs of each of a group of hamsters are shaved. To one organ of each animal 10 μ l. of vehicle alone once a

- 5 -

day is applied, while to the other organ of each animal an equal amount of vehicle containing a aminoacyl-tRNA inhibitor is applied. After thirteen applications (one application per day for five days a week), the flank organs are shaved and the amount of recovered hair (hair mass) from each is weighed. Percent-reduction of

5 hair growth is calculated by subtracting the hair mass (mg) value of the test compound treated side from the hair mass value of the vehicle treated side; the delta value obtained is then divided by the hair mass value of the vehicle treated side, and the resultant number is multiplied by 100.

The above-described assay will be referred to herein as the "Golden

10 Syrian hamster" assay. Preferred compositions provide a reduction in hair growth of at least about 25%, more preferably at least about 50%, and most preferably at least about 60% when tested in the Golden Syrian hamster assay. A number of compositions containing an aminoacyl-tRNA synthetase inhibitor were tested in the Golden Syrian hamster assay; the results are provided in Table 1:

- 6 -

TABLE 1

Inhibitor	Dose (%)	Vehicle	pH	Treated (mg)	Control (mg)	%Inhibition
S-trityl-L-cysteine	7.5	A	6.5	0.35 ± .10	1.64 ± .14	80 ± 6
L-asparaginamide	10	B	5	1.00 ± .24	2.60 ± .42	66 ± 7
4-aza-DL-leucine•2HCL	10	B	5.5	0.70 ± .08	2.02 ± .27	66 ± 3
DL-α-amino-ε-caprolactam	10	D	6.6	0.90 ± .16	2.30 ± .11	59 ± 9
DL-serine hydroxamate	10	B	7.5	1.28 ± .17	2.94 ± .34	56 ± 5
proflavine hemisulfate	10	C	5.5	1.41 ± .19	3.04 ± .24	52 ± 7
L-isoleucinol	10	B	7.5	1.20 ± .21	2.40 ± .38	51 ± 9
N-phenylglycine	10	D	3.0	1.37 ± .19	2.84 ± .22	51 ± 8
L-leucinol	10	E	8.0	1.55 ± .22	2.86 ± .34	46 ± 4
L-prolinol	10	B	7.5	1.31 ± .19	2.43 ± .26	45 ± 6
L-histidonal	10	D	7.4	1.88 ± .26	3.46 ± .18	45 ± 7
L-methioninol	10	E	7.5	1.55 ± .14	2.72 ± .27	42 ± 3
phe-leu-amide	10	F	4.5	1.18 ± .23	1.95 ± .19	41 ± 8
tyramine	10	B	5.0	1.20 ± .19	2.10 ± .13	41 ± 10
3,4-dehydro-DL-proline	10	B	6.0	1.18 ± .18	2.00 ± .11	39 ± 9
DL-β-hydroxynorvaline	10	B	6.0	0.81 ± .15	1.40 ± .11	38 ± 13
S-carbamyl-L-cysteine	7.5	G	4.5	1.71 ± .17	2.55 ± .29	32 ± 6
α-methyl-DL-methionine	15	B	6.5	1.10 ± .15	1.70 ± .40	31 ± 7

Inhibitor	Dose (%)	Vehicle	pH	Treated (mg)	Control (mg)	%Inhibition
L-aspartic acid amide	10	I	6.9	1.38 ± .14	1.99 ± .21	30 ± 5
chloro-L-alanine HLC	10	B	4.5	2.38 ± .27	3.26 ± .26	25 ± 9
cis-hydroxy-proline	10	B	5.5	1.96 ± .18	2.60 ± .22	24 ± 7
DL-4-thiaioleucine	10	B	5.0	2.36 ± .26	3.08 ± .16	23 ± 9
lucinamide	10	B	4.6	2.13 ± .28	2.77 ± .26	22 ± 10
L-tyrprophan hydroxamate	10	H	8	0.88 ± .10	1.10 ± .15	10 ± 17

Vehicles: A--90% H₂O, 6% dipropylene glycol, and 4% ethanol.

B--68% water, 16% ethanol, 5% propylene glycol, 5% dipropylene glycol, 4% benzyl alcohol, and 2% propylene carbonate.

C--92% water, 3% propylene carbonate, and 5% benzyl alcohol.

D--80% ethanol, 17.5% water, 2% propylene glycol dipelargonate (Emerest 2388), and 0.5% propylene glycol.

E--50% dipropylene glycol and 50% ethanol.

F--60% ethanol, 25% dimethyl sulfoxide, 13.1% water, 1.5% propylene glycol dipelargonate (Emerest 2388), and 0.38% propylene glycol.

G--95.6% water and 4.4% dimethyl sulfoxide.

H--100% dimethyl sulfoxide.

I--84% water, 8% ethanol, 2.5% propylene glycol, 2.5% dipropylene glycol, 2% benzyl alcohol, and 1% propylene carbonate.

- 8 -

A dose response study with S-trityl-L-cysteine indicates that increasing the concentration of the inhibitor in the composition resulted in increased hair growth reduction. The results are shown in Table 2.

Table 2

5 Dose response inhibition of hair growth by S-trityl-L-cysteine

Compound	Dose	pH	Treated (mg)	Control (mg)	%Inhibition
S-trityl-L-cysteine	7.5%	6.5	0.35 ± .10	1.64 ± .14	80 ± 6
S-trityl-L-cysteine	5%	6.5	0.90 ± .17	1.95 ± .35	56 ± 6
10 S-trityl-L-cysteine	1%	5.5	0.88 ± .10	1.10 ± .15	35 ± 9

Vehicle: 90% H₂O, 6% dipropylene glycol, nd 4% ethanol

Inhibition of hair follicle aminoacyl-tRNA synthetase as determined using a modification of the procedure described by Hampel et al (Aminoacyl-tRNA Synthetases from Cultured CHO Cells (1979) Methods in Enzymology, Vol. LIX, pp 15 229-234). A reaction mixture containing the following was used for each assay: 50mM Tris (pH 7.4), 15mM MgCl₂, 0.5 mM EDTA (adjusted to pH 7), 5mM ATP (adjusted to pH 7, 0.35 mM CTP, 20 μM ¹⁴C amino acid and tRNA (50μg/ml). Leucine and serine tRNA synthetase were assayed with a pH 8.6 buffer and a MgCl₂ concentration of 8 mM. The reaction mixture is mixed with the hair follicle extract so 20 that the final assay volume is 100 μl. Typically, 90-95 μl of the reaction mixture was mixed with 5-10 μl of the hair follicles extract. The reaction was carried out at 37°C for 60 minutes. The reaction was terminated by removing the reaction mixture and placing it on a piece of filter paper that had been soaked with 10% trichloroacetic acid. The filter paper was washed 3 times in 10% trichloroacetic acid and 3 times in 5% 25 trichloroacetic acid. The filter paper was dried and the insoluble radioactivity, corresponding to the ¹⁴C-aminoacyl-tRNA, was counted in a scintillation counter.

The incorporation of the ¹⁴C amino acid varied from 178 dpm/mM to 3,093 dpm/mM in the assays of the amino acids mentioned above. Using this assay it was found that leucine incorporation into newly synthesized proteins was inhibited

WO 99/15136

PCT/US98/19521

- 9 -

In addition the incorporation of serine into newly synthesized proteins was inhibited 9% by DL-serine hydroxamate.

Other embodiments are within the claims.

- 10 -

CLAIMS

1. A method of reducing mammalian hair growth which comprises selecting an area of skin from which reduced hair growth is desired; and applying to said area of skin a dermatologically acceptable composition
5 comprising an inhibitor of an aminoacyl-tRNA synthetase in an amount effective to reduce hair growth.
2. The method of claim 1, wherein said aminoacyl-tRNA synthetase comprises alanine aminoacyl-tRNA synthetase.
3. The method of claim 1, wherein said aminoacyl-tRNA synthetase
10 comprises arginine aminoacyl-tRNA synthetase.
4. The method of claim 1, wherein said aminoacyl-tRNA synthetase comprises asparagine aminoacyl-tRNA synthetase.
5. The method of claim 1, wherein said aminoacyl-tRNA synthetase comprises aspartic acid aminoacyl-tRNA synthetase.
- 15 6. The method of claim 1, wherein said aminoacyl-tRNA synthetase comprises cysteine aminoacyl-tRNA synthetase.
7. The method of claim 1, wherein said aminoacyl-tRNA synthetase comprises glutamine aminoacyl-tRNA synthetase.
8. The method of claim 1, wherein said aminoacyl-tRNA synthetase
20 comprises glutamic acid aminoacyl-tRNA synthetase.
9. The method of claim 1, wherein said aminoacyl-tRNA synthetase comprises glycine aminoacyl-tRNA synthetase.
10. The method of claim 1, wherein said aminoacyl-tRNA synthetase comprises histidine aminoacyl-tRNA synthetase.
- 25 11. The method of claim 1, wherein said aminoacyl-tRNA synthetase comprises isoleucine aminoacyl-tRNA synthetase.
12. The method of claim 1, wherein said aminoacyl-tRNA synthetase comprises leucine aminoacyl-tRNA synthetase.
13. The method of claim 1, wherein said aminoacyl-tRNA synthetase
30 comprises lysine aminoacyl-tRNA synthetase.
14. The method of claim 1, wherein said aminoacyl-tRNA synthetase comprises methionine aminoacyl-tRNA synthetase.

- 11 -

15. The method of claim 1, wherein said aminoacyl-tRNA synthetase comprises phenylalanine aminoacyl-tRNA synthetase.
16. The method of claim 1, wherein said aminoacyl-tRNA synthetase comprises proline aminoacyl-tRNA synthetase.
- 5 17. The method of claim 1, wherein said aminoacyl-tRNA synthetase comprises serine aminoacyl-tRNA synthetase.
18. The method of claim 1, wherein said aminoacyl-tRNA synthetase comprises threonine aminoacyl-tRNA synthetase.
19. The method of claim 1, wherein said aminoacyl-tRNA synthetase
10 comprises tryptophan aminoacyl-tRNA synthetase.
20. The method of claim 1, wherein said aminoacyl-tRNA synthetase comprises tyrosine aminoacyl-tRNA synthetase.
21. The method of claim 1, wherein said aminoacyl-tRNA synthetase comprises valine aminoacyl-tRNA synthetase.
- 15 22. The method of claim 1, wherein said inhibitor comprises S-trityl-L-cysteine.
23. The method of claim 1, wherein said inhibitor comprises L-asparaginamide.
24. The method of claim 1, wherein said inhibitor comprises 4-aza-DL-
20 leucine.
25. The method of claim 1, wherein said inhibitor comprises DL-serine hydroxamate.
26. The method of claim 1, wherein said inhibitor comprises proflavine (hemisulfate salt).
- 25 27. The method of claim 1, wherein said inhibitor comprises L-isoleucinol.
28. The method of claim 1, wherein said inhibitor comprises N-phenylglycine.
29. The method of claim 1, wherein said inhibitor comprises L-leucinol.
30. The method of claim 1, wherein said inhibitor comprises L-methioninol.
- 30 31. The method of claim 1, wherein said inhibitor comprises phe-leu-amide.
32. The method of claim 1, wherein said inhibitor comprises tyramine.
33. The method of claim 1, wherein said inhibitor comprises L-isoleucinol.

- 12 -

34. The method of claim 1, wherein said inhibitor comprises 3,4-dehydro-DL-proline.
35. The method of claim 1, wherein said inhibitor comprises S-carbamyl-L-cysteine.
- 5 36. The method of claim 1, wherein said inhibitor comprises α -methyl-DL-methionine.
37. The method of claim 1, wherein said inhibitor comprises chloro-L-alanine.
38. The method of claim 1, wherein said inhibitor comprises cis-hydroxy
10 proline.
39. The method of claim 1, wherein said inhibitor comprises L-prolinol.
40. The method of claim 1, wherein said inhibitor comprises t-histidonol.
41. The method of claim 1, wherein said inhibitor comprises L-tyrprophan hydroxamate.
- 15 42. The method of claim 1, wherein said inhibitor comprises thioisoleucine.
43. The method of claim 1, wherein said inhibitor comprises DL-amino- ϵ -caprolactam.
44. The method of claim 1, wherein said inhibitor comprises L-aspartic acid amide.
- 20 45. The method of claim 1, wherein said inhibitor comprise DL- β -hydroxynorvaline.
46. The method of claim 1, wherein said inhibitor is selected from the group consisting of cis-4-fluoro-L-proline; trans-4-fluoro-L-carboxylic acid; α -methyl-DL-histidine; N-formyl-L-histidine; L-2-amino-3-sulfamoylpropionic acid; L-aspartic acid-
25 β -hydroxamate; β -cyano-L-alanine; selenocystamine; and 4-amino-n-butyric acid amide.
47. The method of claim 1, wherein said inhibitor is selected from the group consisting of DL-5-hydroxylysine; L-lysinhydroxamate; 3-(N-phenylacetyl)amino-2,6-piperidinedione (antineoplaston A10); 4-amino-4 phosphonobutyric acid; ethionamide;
30 1,2-diamino-3(4-imidazolyl) propane (histidinamine); α -methylhisidine; (S)-2-methylbutylamine; L-O-methylthreonine; and DL-armentomycin (2-amino-4,4-dichlorobutyric acid).

- 13 -

48. The method of claim 1, wherein said inhibitor is selected from the group consisting of DL-3-dehydroarmentomycin; DL-3-hydroxyleucine; 5,5,5-trifluoro-DL-leucine; β -(3-aminocyclohexyl)-DL-alanine; DL-p-chloroamphetamine; trans-2,6-diaminohex-4-enoic acid; DL-2,6-diphthalimidocaproic acid methyl ester; DL-5-hydroxylysine; L-lysinhydroxamate; and DL-4-oxalysine.

49. The method of claim 1, wherein said inhibitor is selected from the group consisting of DL-4-selenalysine; L-methioninamide; 2-amino-4-methylhex-4-enoic acid; (1S,2S)-2-amino-1-phenyl-1,3-propanediol; N-benzyl-D-amphetamine; N-benzyl-L-phenylalanine; N-benzyl-D-phenylethylamine; 1,3-his (acetoxy)-2-nitro-1-phenylpropane (fenitropan); and 1,2-diamino-3-(2,6-dichlorophenyl) propane.

50. The method of claim 1, wherein said inhibitor is selected from the group consisting of 1,2-diamino-3-hydroxy-5-phenylpentane; 1,2-diamino-3-phenylpropane; N-(2,6-dichlorobenzylidene)-2-phenylethylamine; N-(2,6-dichlorobenzyl)-2-phenylethylamine; N-(4-fluorobenzyl)-L-phenylalanine; DL-fluorophenylalanine; 2-hydroxyethyl-2-phenylammonium sulfate; methyl-DL-phenylalanine; L-phenylalaninol; and L- α -phenylglycine.

51. The method of claim 1, wherein said inhibitor is selected from the group consisting of DL-threo- β -phenylserine; β -2-thienyl-DL-alanine; N-trifluoroacetyl-L-phenylalanine cyclohexyl ester; 2-aminomethyl-4-isopropylpyrrolidine oxalate; 2-amino-methylpyrrolidine; L-4-thiaproline; N-benzylethanolamine; N-(2,6-dichlorobenzyl)ethanolamine; N-(2,6-dichlorobenzylidene)ethanolamine; and DL- β -hydroxyleucine.

52. The method of claim 1, wherein said inhibitor is selected from the group consisting of 1,2-diamino-5-phenyl-3-pentanol; DL-7-azatryptophan; DL-fluorotryptophan; 5-hydroxytryptamine; L-5-hydroxy-tryptophan; DL- α -methyltryptamine; methyl-DL-tryptophan; tryptamine; DL-2-amino-1-(4-hydroxyphenyl)-1-propanol; and DL-3-fluorotyrosine.

53. The method of claim 1, wherein said inhibitor is selected from the group consisting of 3-iodo-L-tyrosine; 3-nitro-L-tyrosine; L-tyrosinol $\cdot$ HC1; L-threo-2-amino-3-chlorobutyric acid; hexafluoro-DL-valine; DL-norvaline; L-4-thialysine; DL-ethionine; N,N'-di-CBZ-L-lysine; DL-3-fluorophenylalanine; DL-4-fluorophenylalanine; and DL-3,4-dihydroxyphenylalanine.

- 14 -

54. The method of claim 1, wherein the concentration of said inhibitor of in said composition is between 0.1% and 30%
55. The method of claim 1, wherein the composition provides a reduction in hair growth of at least 20% when tested in the Golden Syrian hamster assay..
- 5 56. The method of claim 1, wherein the composition provides a reduction in hair growth of at least 50% when tested in the Golden Syrian hamster assay.
57. The method of claim 1, wherein the composition provides a reduction in hair growth of at least 60% when tested in the Golden Syrian hamster assay.
58. The method of claim 1, wherein the inhibitor is applied to the skin in an
10 amount of from 10 to 3000 micrograms of said inhibitor per square centimeter of skin.
59. The method of claim 1, wherein said mammal comprises a human.
60. The method of claim 59, wherein said area of skin is on the face of the human.
61. The method of claim 59, wherein said area of skin is on a leg of the
15 human.
62. The method of claim 59, wherein said area of skin is on an arm of the human.
63. The method of claim 59, wherein said area of skin is in an armpit of the human.
- 20 64. The method of claim 59, wherein said area of skin in on the torso of the human.
65. The method of claim 59, wherein said human is a woman suffering from hirsutism.
66. The method of claim 1, wherein said hair growth comprises androgen-
25 stimulated hair growth.
67. A method according to any one of claims 1 to 66, wherein said applying of said inhibitor has a cosmetic effect.
68. A method of producing a composition for inhibiting mammalian hair growth, with comprises selecting an inhibitor of an aminoacyl-tRNA synthetase, and
30 combining said inhibitor, in an amount effective to reduce hair growth, with a non-toxic, dermatologically acceptable vehicle or carrier.
69. A method according to claim 68, wherein said vehicle or carrier is

- 15 -

adapted to be spread upon the skin of a mammal.

70. A method according to claim 68 or 69, wherein a cosmetic composition is produced.

71. A method according to claim 68, wherein said inhibitor is as defined in
5 any one of claims 2-53.

72. The new use of an inhibitor of aminoacyl-tRNA synthetase for reducing hair growth.

73. A composition when used for inhibiting mammalian hair growth, which includes an inhibitor of an aminoacyl-tRNA synthetase, in an amount effective to
10 reduce hair growth, and a non-toxic, dermatologically acceptable vehicle or carrier.

74. A composition according to claim 73, wherein said inhibitor is as defined in any one of claims 2-53.

75. A composition according to claim 73, which is a cosmetic composition.